Viridian Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Viridian Therapeutics Inc VRDN.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.00. The mean expectation of fifteen analysts for the quarter was for a loss of $1.08 per share. Wall Street expected results to range from $-1.30 to -60 cents per share.

• Revenue rose 53.5% to $70.57 million from a year ago; analysts expected $12.73 million.

• Viridian Therapeutics Inc's reported EPS for the quarter was a loss of $1.08​.

• The company reported a quarterly loss of $28.17 million.

• Viridian Therapeutics Inc shares had fallen by 7.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Viridian Therapeutics Inc is $42.00, about 31.1% above its last closing price of $28.94

This summary was machine generated from LSEG data February 26 at 04:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)